November 12th, 2026Oral Enlicitide Could Close Primary Prevention Gap: Christie Ballantyne, MDIn this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.Read more
November 10th, 2026How Plans, Clinicians Should Handle Gray-Market RetatrutideIn this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.Read more